Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2006 2
2008 1
2009 3
2010 2
2011 3
2012 1
2013 5
2014 9
2015 4
2016 8
2017 12
2018 9
2019 13
2020 37
2021 40
2022 34
2023 28
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

181 results

Results by year

Filters applied: . Clear all
Page 1
Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic.
de Sèze J, Maillart E, Gueguen A, Laplaud DA, Michel L, Thouvenot E, Zephir H, Zimmer L, Biotti D, Liblau R. de Sèze J, et al. Among authors: maillart e. Front Immunol. 2023 Mar 23;14:1004795. doi: 10.3389/fimmu.2023.1004795. eCollection 2023. Front Immunol. 2023. PMID: 37033984 Free PMC article. Review.
Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society.
Vukusic S, Carra-Dalliere C, Ciron J, Maillart E, Michel L, Leray E, Guennoc AM, Bourre B, Laplaud D, Androdias G, Bensa C, Bigaut K, Biotti D, Branger P, Casez O, Cohen M, Daval E, Deschamps R, Donze C, Dubessy AL, Dulau C, Durand-Dubief F, Guillaume M, Hebant B, Kremer L, Kwiatkowski A, Lannoy J, Maarouf A, Manchon E, Mathey G, Moisset X, Montcuquet A, Pique J, Roux T, Marignier R, Lebrun-Frenay C. Vukusic S, et al. Among authors: maillart e. Mult Scler. 2023 Jan;29(1):11-36. doi: 10.1177/13524585221129472. Epub 2022 Nov 1. Mult Scler. 2023. PMID: 36317497 Review.
[Neuromyelitis optica].
Roux T, Maillart É, Papeix C. Roux T, et al. Among authors: maillart e. Rev Prat. 2023 Jan;73(1):79-83. Rev Prat. 2023. PMID: 36820464 French.
Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Chen JJ, Huda S, Hacohen Y, Levy M, Lotan I, Wilf-Yarkoni A, Stiebel-Kalish H, Hellmann MA, Sotirchos ES, Henderson AD, Pittock SJ, Bhatti MT, Eggenberger ER, Di Nome M, Kim HJ, Kim SH, Saiz A, Paul F, Dale RC, Ramanathan S, Palace J, Camera V, Leite MI, Lam BL, Bennett JL, Mariotto S, Hodge D, Audoin B, Maillart E, Deschamps R, Pique J, Flanagan EP, Marignier R. Chen JJ, et al. Among authors: maillart e. JAMA Neurol. 2022 May 1;79(5):518-525. doi: 10.1001/jamaneurol.2022.0489. JAMA Neurol. 2022. PMID: 35377395 Free PMC article.
How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP).
Bigaut K, Cohen M, Durand-Dubief F, Maillart E, Planque E, Zephir H, Lebrun-Frenay C, de Seze J; French Group for Recommendations in Multiple Sclerosis (France4MS) and the Société Française de la Sclérose En Plaques (SFSEP). Bigaut K, et al. Among authors: maillart e. Mult Scler Relat Disord. 2021 Aug;53:103076. doi: 10.1016/j.msard.2021.103076. Epub 2021 Jun 10. Mult Scler Relat Disord. 2021. PMID: 34161898
Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder.
Demuth S, Collongues N, Audoin B, Ayrignac X, Bourre B, Ciron J, Cohen M, Deschamps R, Durand-Dubief F, Maillart E, Papeix C, Ruet A, Zephir H, Marignier R, De Seze J; NOMADMUS Study Group. Demuth S, et al. Among authors: maillart e. Neurology. 2023 Jul 25;101(4):e438-e450. doi: 10.1212/WNL.0000000000207443. Epub 2023 Jun 8. Neurology. 2023. PMID: 37290967
Multiple sclerosis and aging.
Louapre C, Papeix C, Lubetzki C, Maillart E. Louapre C, et al. Among authors: maillart e. Geriatr Psychol Neuropsychiatr Vieil. 2017 Dec 1;15(4):402-408. doi: 10.1684/pnv.2017.0685. Geriatr Psychol Neuropsychiatr Vieil. 2017. PMID: 29081400 Review. English.
A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing-remitting multiple sclerosis.
Louapre C, Rosenzwajg M, Golse M, Roux A, Pitoiset F, Adda L, Tchitchek N, Papeix C, Maillart E, Ungureanu A, Charbonnier-Beaupel F, Galanaud D, Corvol JC, Vicaut E, Lubetzki C, Klatzmann D. Louapre C, et al. Among authors: maillart e. J Neurol. 2023 Sep;270(9):4403-4414. doi: 10.1007/s00415-023-11690-6. Epub 2023 May 28. J Neurol. 2023. PMID: 37245191 Clinical Trial.
Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis.
Januel E, Hajage D, Labauge P, Maillart E, De Sèze J, Zephir H, Pelletier J, Guilloton L, Bensa C, Heinzlef O, Casez O, Biotti D, Bourre B, Vukusic S, Maurousset A, Berger E, Laplaud D, Lebrun-Frénay C, Dubessy AL, Branger P, Thouvenot E, Clavelou P, Sellal F, Manchon E, Moreau T, Papeix C, Tubach F, Louapre C. Januel E, et al. Among authors: maillart e. JAMA Netw Open. 2023 Jun 1;6(6):e2319766. doi: 10.1001/jamanetworkopen.2023.19766. JAMA Netw Open. 2023. PMID: 37351881 Free PMC article.
181 results